Mitsubishi Tanabe Pharma Corporation

Osaka University

Eiji Kawanishi

Sumihiro Nomura

Kiichiro Ueta

Satoshi Obika

Yoshihito Tanaka

Hiroaki Sawamoto

Toshiaki Sakamoto

Mitsuya Hongu

Shuhei Yamakoshi

Shinji Kumagai

Hiroshi Morimoto

Yuuki Aral

Takehiko Matsumura

Toshiyuki Himiyama

Yuuki Arai

A method for preparing a compound represented by general formula I: or a salt thereof includes a step of reacting a compound represented by formula II: with a reducing agent to cleave an oxazolidine ring fused to a cycle A'. The reducing agent includes at least one of phosphines, metal hydrides, or transition metal catalysts in the presence of hydrogen gas.

Bridged nucleic acid GuNA, method for producing same, and intermediate compound

The present invention relates to a compound represented by formula [I]: wherein:

Pyrazolopyrimidine compounds and their use as PDE10 inhibitors

A compound of the formula: wherein Ring A and Ring B are: (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring or an optionally substituted unsaturated fused heterobicyclic ring, or (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, and Ring B are independently an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; X is a carbon atom or a nitrogen atom; Y is &#x2014;(CH)&#x2014; (n is 1 or 2); or a pharmaceutically acceptable salt thereof, or a prodrug thereof.

Glucopyranoside compound

A novel crystal form of 1-(&#x3b2;-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate, and having favorable characteristics, is characterized by its x-ray powder diffraction pattern and/or by its infra-red spectrum.

Crystalline form of 1-(&#x3b2;-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate

Crystalline form of 1-(&#x3b2;-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate

A compound of the formula: wherein Ring A and Ring B are: (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring or an optionally substituted unsaturated fused heterobicyclic ring, or (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, and Ring B are independently an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; X is a carbon atom or a nitrogen atom;

Growing community of inventors

Osaka, Japan

Eiji Kawanishi